Figure 5.
Percentage of treatment limiting infusion reactions in aCL(+) patients compared with all patients in the registry (infliximab treatment only). Comparison is by χ2 test.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.